Last Updated: Jan 15 2009 - Able2Act


Fact Sheet for Purdue Pharma L.P.

Country: USA
Contact: Purdue Pharma L.P.One Stamford ForumStamford, CT 06901 United States
Homepage: http://www.purduepharma.com
Comments: Purdue Pharma offers Cost-free training and educational materials regarding prescription drug abuse and diversion.
Compilation by Silobreaker
Although Silobreaker has relied on what it regards as reliable sources while compiling the content herein, Silobreaker cannot guarantee the accuracy, completeness, integrity or quality of such content and no responsibility is accepted by Silobreaker in respect of such content. Readers must determine for themselves what reliance they should place on the compiled content herein.

Related Stories

First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

FDA Grants Priority Review Designation for Purdue Pharma's Once-Daily Hydrocodone Bitartrate Extended-Release Tablets Formulated with Abuse-Deterrent Properties

By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) has granted Priority Review designation for the company's once-daily, single-entity hydrocodone bitartrate ... [Published HighBeam Research - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

FDA Approves Purdue Pharma’s Abuse-Deterrent Painkiller

The FDA approved only the second extended-release opioid painkiller to feature abuse-deterrent properties, and hinted that future products with such technologies could receive faster regulatory reviews.Purdue Pharma’s Targiniq ER (oxycodone HCl and naloxone ... [Published FDA News - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

FDA Approves Purdue Pharma L.P.???s Hard-to-Abuse Narcotic Painkiller

FDA Approves Purdue Pharma’s Hard-to-Abuse Narcotic PainkillerJuly 28, 2014By Renee Morad , BioSpace.com Breaking News StaffThe Food and Drug Administration approved a drug combining oxycodone and naloxone that is designed to discourage abuse by those ... [Published BioSpace - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Studies Examining the Relationship between the Chemical Structure of Protoxin II and Its Activity on Voltage Gated Sodium Channels

Discovery Research, Purdue Pharma L.P., 6 Cedar Brook Drive, Cranbury, New Jersey 08512, United States ... [Published Journal of Medicinal Chemistry - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 3 reports

FDA approves Targiniq ER from Purdue Pharma

SILVER SPRING, Md. — The Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets). The drug is an extended-release, long-acting opioid analgesic that treats pain severe enough to require ... [Published Drug Store News - Jul 24 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Purdue Pharma gets FDA approval for 7.5 mcg/hour dosage strength of Butrans transdermal system CIII

Purdue Pharma has announced that the US Food & Drug Administration (FDA) has approved a new 7.5 mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII. Five strengths of Butrans will now be available: 5 mcg/hour, 7.5 mcg/hour, 10 ... [Published PBR - News - Jul 21 2014]
First reported Jul 16 2014 - Updated Jul 17 2014 - 4 reports

Purdue cleared to market additional strength of Butrans patch

STAMFORD, Conn. – Purdue Pharma has received approval from the Food and Drug Administration for a new 7.5 mcg/hour dosage strength of the Butrans Transdermal System CIII, an opioid pain medication patch.Purdue said Wednesday that five strengths of Butrans ... [Published Chain Drug Review - Jul 17 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Purdue Pharma receives priority review designation from FDA for pain drug

Purdue Pharma L.P., a research-based company, has received priority review designation from FDA for the company's once-daily, single-entity hydrocodone bitartrate tablet, or HYD. This investigational pain medication was formulated to incorporate abuse-deterrent ... [Published Individual.com - Jul 15 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 2 reports

Priority Review for Purdue’s anti-abuse hydrocodone

The US FDA has granted Priority Review Designation to Purdue Pharma’s hydrocodone bitartrate tablet which has abuse-deterrent technology.Priority Review is given by the FDA to drugs that could make major improvements to treatment of serious conditions, ... [Published In-Pharmatechnologist - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 3 reports

KBR To Construct Oral Solid Dosage Production Facility For Purdue Pharma Manufacturing L.P. In Durham, N.C.

KBR (NYSE: KBR) announced today that KBR Building Group, a subsidiary within KBR's Services Group, has been awarded a contract by Purdue Pharma Manufacturing L.P. to build a new Oral Solid Dosage manufacturing plant in Durham, N.C. The 188,000-square-foot, ... [Published EPC Engineer - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 3 reports

FDA grants Priority Review designation for Purdue’s hydrocodone bitartrate

Privately held US drugmaker Purdue Pharma has been granted Priority Review designation by the US Food and Drug Administration for its once-daily, single-entity hydrocodone bitartrate tablet.This has been formulated with abuse-deterrent properties that ... [Published Pharma Letter - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 3 reports

Purdue pain drug gets priority status

Share this article: Purdue Pharma announced Tuesday that the Food and Drug Administration has granted Priority Review to its experimental hydrocodone bitartrate tablet. The Connecticut drugmaker expects the FDA will review the daily, extended release ... [Published Medical Marketing And Media - Jul 09 2014]
In Focus
Network
Network

Blogs

sort by: Date | Relevance
Purdue Pharma L.P. Names Mark Timney President ... [Published PR Newswire: Health - Jan 27 2014]
STAMFORD, Conn., Jan. 27, 2014 /PRNewswire/ -- Purdue Pharma L.P. today announced that the company's Board of Directors has appointed Mark Timney as President and Chief Executive Officer."We found a proven leader in Mark Timney," said Dr. Raymond Sackler, ...
Purdue Pharma L.P. Names Saeed Motahari Senior ... [Published PR Newswire: Health - May 22 2014]
STAMFORD, Conn., May 22, 2014 /PRNewswire/ -- Purdue Pharma L.P. today announced that Saeed Motahari has joined the company as Senior Vice President and Chief Commercial Officer."We welcome Saeed to the Purdue team. I am confident that his impressive ...
Purdue Pharma L.P. Presents Data from Research ... [Published PR Newswire: General Business - Apr 29 2014]
STAMFORD, Conn., April 29, 2014 /PRNewswire/ -- Purdue Pharma L.P. will present results from a number of research studies at the American Pain Society (APS) 33rd Annual Scientific Meeting, April 30-May 3, 2014, in Tampa, Fla.Following is a schedule of ...
Purdue Pharma L.P. Announces Positive Phase 3 C... [Published PR Newswire: Health - Mar 12 2014]
STAMFORD, Conn., March 12, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that a Phase 3 study of an investigational extended-release formulation of hydrocodone bitartrate met its primary efficacy endpoint by showing that patients with chronic low ...
MS CONTIN (Morphine Sulfate) Tablet, Film Coate... [Published DailyMed Drug Label Updates for the last seven ... - Jun 22 2014]
Updated Date: Jun 19, 2014 EST ...
1 2 3 4

Press Releases

sort by: Date | Relevance
Purdue Pharma L.P., a Leading Pharmaceutical Co... [Published Financial Services - Jun 18 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.